Navigating The Uncharted Waters Of EU HTA

 
• By Alexander Natz and Matias Olsen

The EU-level joint clinical assessments that will be introduced under the Health Technology Assessment Regulation from January 2025 represent a huge shift for drug companies launching products in the EU. Industry experts Alexander Natz and Matias Olsen offer key advice to help companies prepare for what is to come.

Sailing boat crossing the sea
EUCOPE sets out how companies can navigate the new EU-wide joint clinical assessments, which represent a major change to the bloc's market access environment.

More from Pink Sheet

More from Europe